The growing adoption of MeMed BV in emergency medicine, urgent care, and hospital settings indicates the industry's move toward host-response and precision diagnostics. From hospital systems to ...
Memed Diagnostics Ltd. has published new data from an EU Commission funded clinical trial evaluating its blood test for differentiating bacterial and viral infections. The prospective, multicenter ...
—MeMed BV Flex™ simultaneously measures multiple host proteins, paired with machine learning, to deliver highly accurate results in 15 minutes from just a few drops of blood— —Designed for use in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MeMed Ltd. announced that it has received a government ...
The MarketWatch News Department was not involved in the creation of this content. ANDOVER, Mass. and HAIFA, Israel, March 25, 2026 /CNW/ -- MeMed, a leader in host-response technology, today announced ...
Hosted on MSN
MeMed develops rapid infection differentiation test
MeMed has developed MeMed BV Flex, a rapid infection differentiation test that distinguishes between bacterial and viral infections. This test is set to widen the accessibility of MeMed BV to ...
ANDOVER, Mass. & HAIFA, Israel--(BUSINESS WIRE)--MeMed, a leader in host-response diagnostics, today announced the addition of three distinguished experts to its advisory board to accelerate its ...
While most infectious disease tests search a sample for the presence of a particular pathogen, MeMed’s diagnostic collects evidence from the immune system itself and helps identify the culprit by ...
Israeli diagnostics company MeMed was just awarded $9.2 million from the U.S. Defense Threat Reduction Agency (DTRA) to develop a faster instrument to differentiate between bacterial and viral ...
TIRAT CARMEL, Israel--(BUSINESS WIRE)--MeMed Ltd. announced today notification of a €3 million award for the company’s Respiratory-ImmunoDx project from the European Commission. The three-year award ...
MeMed has raised over $70 million to support its point-of-care immune system diagnostic for distinguishing between bacterial and viral infections. The company aims to cut down on the misuse of ...
– Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management – – MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results